Institute of Biomedical Research Corp
Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental … Read more
Institute of Biomedical Research Corp (MRES) - Net Assets
Latest net assets as of March 2025: $2.54 Million USD
Based on the latest financial reports, Institute of Biomedical Research Corp (MRES) has net assets worth $2.54 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.31 Million) and total liabilities ($775.72K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.54 Million |
| % of Total Assets | 76.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | 146.47% |
| 10-Year Change | N/A |
| Growth Volatility | 53.95 |
Institute of Biomedical Research Corp - Net Assets Trend (2006–2025)
This chart illustrates how Institute of Biomedical Research Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Institute of Biomedical Research Corp (2006–2025)
The table below shows the annual net assets of Institute of Biomedical Research Corp from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $2.54 Million | -0.56% |
| 2024-03-31 | $2.55 Million | +2205.63% |
| 2023-03-31 | $-121.21K | -110.99% |
| 2015-03-31 | $1.10 Million | +7.09% |
| 2014-03-31 | $1.03 Million | +332.69% |
| 2013-03-31 | $-442.50K | -28.18% |
| 2010-03-31 | $-345.21K | -380.72% |
| 2009-03-31 | $-71.81K | +12.87% |
| 2008-03-31 | $-82.42K | +28.96% |
| 2006-03-31 | $-116.02K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Institute of Biomedical Research Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5755287900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.66 Million | 456.20% |
| Other Components | $56.98 Million | 9758.42% |
| Total Equity | $583.87K | 100.00% |
Institute of Biomedical Research Corp Competitors by Market Cap
The table below lists competitors of Institute of Biomedical Research Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Apollomics Inc. Warrant
NASDAQ:APLMW
|
$132.88 |
|
SURNF
OTCQB:SURNF
|
$133.19 |
|
Anglo Philippine Holdings Corp
PSE:APO
|
$133.50 |
|
SCOA NIGERIA PLC
XNSA:SCOA
|
$133.60 |
|
Synergia Energy Ltd.
LSE:SYN
|
$132.62 |
|
CWG PLC
XNSA:CWG
|
$132.18 |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
$131.77 |
|
REFLEX ADVANCED MAT.
F:HF2
|
$131.55 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Institute of Biomedical Research Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,483,654 to 583,870, a change of -899,784 (-60.6%).
- Net loss of 632,720 reduced equity.
- Other factors decreased equity by 267,064.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-632.72K | -108.37% |
| Other Changes | $-267.06K | -45.74% |
| Total Change | $- | -60.65% |
Book Value vs Market Value Analysis
This analysis compares Institute of Biomedical Research Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 64.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | $-0.06 | $0.01 | x |
| 2005-03-31 | $-0.09 | $0.01 | x |
| 2006-03-31 | $-0.09 | $0.01 | x |
| 2007-03-31 | $-0.01 | $0.01 | x |
| 2008-03-31 | $-0.03 | $0.01 | x |
| 2009-03-31 | $-0.02 | $0.01 | x |
| 2010-03-31 | $-0.06 | $0.01 | x |
| 2023-03-31 | $0.00 | $0.01 | x |
| 2024-03-31 | $0.00 | $0.01 | x |
| 2025-03-31 | $0.00 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Institute of Biomedical Research Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -108.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1278.56%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 5.68x
- Recent ROE (-108.37%) is below the historical average (6.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.13K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.04K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-165.28K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-688.13K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.36 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-436.11K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-238.88K |
| 2013 | 0.00% | -5.56% | 0.56x | 0.00x | $15.21K |
| 2014 | 50.90% | 46.39% | 0.23x | 4.80x | $421.14K |
| 2015 | 51.21% | 40.08% | 0.27x | 4.79x | $454.40K |
| 2023 | 0.00% | -1471.97% | 0.05x | 0.00x | $-421.28K |
| 2024 | 89.63% | 2950.33% | 0.01x | 2.35x | $1.18 Million |
| 2025 | -108.37% | -1278.56% | 0.01x | 5.68x | $-691.11K |
Industry Comparison
This section compares Institute of Biomedical Research Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Institute of Biomedical Research Corp (MRES) | $2.54 Million | 0.00% | 0.31x | $132.71 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |